What are the possible reactions after taking vemurafenib/zobovo?

As a BRAF inhibitor, Vemurafenib/Zobovo(Vemurafenib), while bringing clinical benefits, may also produce a series of adverse reactions. This is a problem that patients and doctors must face together during the medication process. The most common adverse reactions are concentrated on the skin, such as rash, itching, photosensitivity reactions, and cutaneous squamous cell carcinoma. These manifestations are related to the drug's effect on the BRAF pathway in skin cells. Therefore, patients need to undergo regular dermatological examinations during the medication period to detect and treat potential lesions in a timely manner.

In addition to skin manifestations, some patients may experience joint pain, myalgia, fatigue, and hair loss. Most of these symptoms are mild to moderate and can be relieved through symptomatic treatment. Digestive discomfort such as nausea and loss of appetite are also common, but do not usually lead to discontinuation of medication. Special attention needs to be paid to the effects on the heart and liver. Some patients may experience prolonged QT interval or elevated liver function indicators. Therefore, electrocardiograms and liver function tests must be performed regularly during medication to ensure medication safety. A small number of patients may also develop eye problems, such as blurred vision or uveitis, which require prompt medical treatment.

Resistance is a challenge that cannot be ignored in long-term treatment with vemurafenib. As the drug is taken for a longer period of time, cancer cells may regain their ability to proliferate through alternative signaling pathways, resulting in drug failure. In order to deal with this problem, treatment options combined with MEK inhibitors have gradually become popular. Through dual inhibition of key signaling pathways, they can effectively delay the occurrence of drug resistance and improve the survival benefits of patients.

Overall, the adverse reactions of vemurafenib are controllable in most cases, and with standard follow-up and medication adjustments, patients can still obtain significant curative effects. This also reminds patients to closely cooperate with their doctors during medication and follow monitoring and management measures to balance efficacy and risks to the greatest extent.

Reference: https://www.drugs.com/mtm/vemurafenib.html